December 15, 2017 / 12:44 AM / 6 months ago

BRIEF-Pfizer Announces FDA Approval Of Xeljanz® And Xeljanz® Xr For Treatment Of Active Psoriatic Arthritis

Dec 14 (Reuters) - Pfizer Inc:

* PFIZER ANNOUNCES FDA APPROVAL OF XELJANZ® (TOFACITINIB) AND XELJANZ® XR FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS

* SAYS ‍BOTH PIVOTAL STUDIES MET THEIR TWO PRIMARY EFFICACY ENDPOINTS​

* ‍SAFETY PROFILE OBSERVED IN PATIENTS TREATED WITH XELJANZ CONSISTENT WITH SAFETY PROFILE OBSERVED IN RHEUMATOID ARTHRITIS PATIENTS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below